Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

For the majority of people with the virus in the U.S., dying with HIV has turned into living a long life with HIV.

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Discover why starting HIV treatment promptly preserves immune function, prevents transmission, improves quality of life and reduces costs ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

Emory University's pioneering work with a class of small molecules known as JAK (janus kinase) inhibitors continues to show how HIV might be cured ...